Sentences with phrase «myeloma research»
United States About Blog The latest lymphoma, leukemia and myeloma research from prestigious universities and journals throughout the world.
https://blog.feedspot.com/
United States About Blog The latest lymphoma, leukemia and myeloma research from prestigious universities and journals throughout the world.
Precious Cat Litter has teamed up with the Multiple Myeloma Research Foundation (MMRF) for its #CatsAgainstCancer campaign, which aims to raise awareness and find a cure for multiple myeloma, a rare form of blood cancer.
While there traditionally hasn't been a lot of options for people with multiple myeloma, the Multiple Myeloma Research Foundation has been successful at bringing more drugs to market, by far, than any other cancer organization.
Is an honorary board member of the Multiple Myeloma Research Foundation.
He was the founding Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core and now chairs the Multiple Myeloma Committee for the Alliance for Clinical Trials in Oncology (the former CALGB).
The Multiple Myeloma Research Foundation (MMRF) and its sister research organization, the 22 - member Multiple Myeloma Research Consortium (MMRC), have created a remarkable engine for drug discovery and development in a very short time.
As a new member of the elite Multiple Myeloma Research Foundation, we have access to even more new treatments earlier than other facilities, and we are supporting the continued advancement of myeloma therapies.
Participants included CEOs Jonathan Bush of Athenahealth, Ron Gutman of HealthTap, Dr. Clifford Hudis of the American Society of Clinical Oncology, Dr. Vivian Lee of University of Utah Health Care, VitalConnect CEO Nersi Nazari, James Park of Fitbit, and Andrew Witty of GSK, as well as President of Flex Health Solutions John Carlson, Multiple Myeloma Research Foundation Founder Kathy Giusti, Dr. Sanjay Gupta, Arianna Huffington, Andreessen Horowitz General Partner Vijay Pande, Parker Foundation President Sean Parker, Women's Alzheimer's Movement Founder Maria Shriver, and White House Cancer Moonshot Task Force Executive Director Greg Simon.
Deborah Brooks, Co-founder and Executive Vice President, The Michael J. Fox Foundation for Parkinson's Research Kathy Giusti, Founder, Multiple Myeloma Research Foundation & Consortium Sean Lane, CEO and Co-Founder, Crosschx Claudia Williams, Senior Advisor, White House Office of Science and Technology Policy Moderator: Rik Kirkland, Partner, Global Publishing, McKinsey & Co..
The mission of the Multiple Myeloma Research Foundation (MMRF) is to accelerate next generation multiple myeloma treatments to extend patients» lives in pursuit of a cure.
MMRF, a 501 (c)(3), is the number one private funder of multiple myeloma research in the United States.
THE PATIENT AS INNOVATOR With Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy Giusti of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co. — Report by Kia Kokalitcheva — Video: Patients Should Get Access to Their Health Data
4:05 pm: Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy Giusti of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co..
Within weeks of her diagnosis in 1996, Giusti began disrupting the myeloma research culture — getting isolated doctors and scientists to share data, and building an unheard - of consortium to develop drugs.
And that, of course, was a very different reason from the one that had brought him and his fellow lunch mates to gather that afternoon — at a day of scientific panels and presentations sponsored by the Multiple Myeloma Research Foundation.
When Kathy Giusti founded the Multiple Myeloma Research Foundation, there were no drugs for the blood cancer.
Not exact matches
Announcing the first ever research program solely dedicated to the early detection and prevention of Multiple Myeloma Learn More
After his illness was diagnosed, Mr. Cassidy organized two fundraisers at Buffalo Grove High School: a «liftathon,» in which teams of students and staff lifted weights for pledges for the International Myeloma Foundation, and a «walkathon» for cancer research.
According to Cancer Research UK, each year Britain diagnoses 4,000 new Myeloma cases and 2,500 Myeloma sufferers die.
Sen. Charles Schumer says research has found a strong connection between firefighting and an increased risk for several major cancers including testicular, stomach, multiple myeloma and brain cancers.
«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.
«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.
The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.
DeCicco - Skinner's research suggests a new approach for the treatment of multiple myeloma.
Little research into multiple myeloma examines varying patient weight to see how cells encourage cancer growth.
«Research team first to identify AF1q protein associated with multiple myeloma, extramedullary disease.»
New research shows that excess weight increases the risk that a benign blood disorder will progress into multiple myeloma, a cancer of the blood.
«We are excited by the work of Dr. Pourdehnad and colleagues and believe these results are an important advance in understanding the role of myc pathway dysregulation in multiple myeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the remyeloma, and ultimately allow for the development of therapeutic strategies to address it,» said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the reMyeloma Translational Initiative at UCSF, a sponsor of the research.
«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical Myeloma Center, and the R.J. Corman professor at Harvard Medical School.
«Our research highlights a potentially new mechanism of dinaciclib action, and raises the possibility that this agent could be a useful addition to current multiple myeloma and myeloid leukemia therapies.»
«We've known about these cells blocking immune response for a decade, but haven't been able to shut them down for lack of an identified target,» said the paper's senior author, Larry Kwak, M.D., Ph.D., chair of Lymphoma / Myeloma and director of the Center for Cancer Immunology Research at The University of Texas MD Anderson Cancer Center.
«Updated criteria for diagnosing multiple myeloma published by international research group.»
A new study by researchers at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014
This research provides the basis for developing new and more targeted treatments and minimally invasive ways of identifying those MGUS patients at risk of progressing to myeloma.
Dr Daniel Tennant, who led the research at the University of Birmingham, said, «Our findings show that very few changes are required for a MGUS patient to progress to myeloma as we now know virtually all patients with myeloma evolve from MGUS.
Dr Matt Kaiser, Head of Research at Bloodwise, said, «Myeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost alwaysMyeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost alwaysmyeloma patients, it is ultimately almost always fatal.
The research team found over 200 products of metabolism differed between the healthy volunteers and patients with MGUS or myeloma, compared to just 26 differences between MGUS patients and myeloma patients.
Recent past honorees include Julian Adams of Infinity Pharmaceuticals, Alfred Goldberg of Harvard Medical School and Kenneth Anderson and Paul Richardson, both of Dana - Farber Cancer Institute, for the development of bortezomib, a drug that has altered the lives of hundreds of thousands of people with multiple myeloma; Alain Carpentier of Hôpital Européen Georges Pompidou in Paris and Robert S. Langer of MIT for innovations in bioengineering; and the work of Harald zur Hausen and Lutz Gissmann of the German Cancer Research Center on human papillomavirus (HPV) and cancer of the cervix, which was recognized by the WAFP prior to their receiving the Nobel Prize.
A promising avenue of clinical research in multiple myeloma is the use of immune checkpoint inhibitors.
This page features information on multiple myeloma and immunotherapy clinical trials for multiple myeloma patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to people with multiple myeloma.
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center...
«We explored the relationship between response to initial treatment and survival in patients with newly diagnosed multiple myeloma, based on data from 63 randomized clinical trials,» wrote researcher Maria Mainou, of the clinical research and evidence - based medicine unit at Aristotle University of Thessaloniki, Greece, and colleagues.
His primary research interest is in novel therapies for myeloma, and he has been at the forefront of the clinical development of bortezomib, lenalidomide, and most recently pomalidomide.
Studies have found less of a direct association between obesity and other cancers, including gallbladder, cervical, ovarian, and prostate cancer, as well as Non-Hodgkin lymphoma and multiple myeloma — but research does suggest it may play a role in these diseases, too.
I am a molecular biologist and I do research related to finding therapeutic interventions for a rare type of hematologic cancer called multiple myeloma.
he study reiterates earlier research which shows that prolonged exposure to airborne petroleum hydrocarbons causes «an increased risk of eye irritation and headaches, asthma symptoms, acute childhood leukemia, acute myelogenous leukemia, and multiple myeloma.»